Alvotech and teva announce u.s. fda approval of selarsdi™ (ustekinumab-aekn), biosimilar to stelara® (ustekinumab)

Reykjavik, iceland & parsippany, nj  — alvotech (nasdaq: alvo) and teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced that the u.s. food and drug administration (fda) has approved selarsdi (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. under the strategic partnership between teva and alvotech, teva is responsible for the exclusive commercialization of selarsdi in the united states.
ALVO Ratings Summary
Quant
ALVO Quant Ranking
Sector
Industry
Quant Rating
Quant Score